In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).
Watch the video and download the accompanying slides to learn about:
- The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
- Applying recent data to treatment sequencing in bone-dominant mCRPC
- Educating and supporting patients during treatment so they know what to expect
Clinical Takeaways
- 
Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL 
- 
They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue 
- 
Real-world data support using 177Lu-PSMA in patients who previously received Ra-223 
- 
Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients 
 
                                        
                               
                            
                  
 
       
                         Downloadable
                  Downloadable  MIN
                MIN
             Oct 2025
               Oct 2025             
                         
                            
                            
                            
                            
                                           
                   
                         
                         
                         
                         
                            
                            
                            
                   
                         
                         
                            
                            
                   
                         
                            
                        